Implication of the C-Terminal Domain of Nef Protein in the Reversion to Pathogenicity of Attenuated SIVmacBK28-41 in Macaques  by Lafont, Bernard A.P. et al.
e
K
Virology 266, 286–298 (2000)
doi:10.1006/viro.1999.9991, available online at http://www.idealibrary.com onImplication of the C-Terminal Domain of Nef Protein in the Reversion to Pathogenicity
of Attenuated SIVmacBK28-41 in Macaques
Bernard A. P. Lafont,*,1 Yves Rivie`re,† Liliane Gloeckler,* Christian Beyer,* Bruno Hurtrel,‡
Marie Paule Kieny,§ Andre´ Kirn,* and Anne Marie Aubertin*
*INSERM U-74 et Laboratoire de Virologie, 3 rue Koeberle´, 67000 Strasbourg, France; †Laboratoire d’Immunopathologie Virale, Institut Pasteur,
75015 Paris, France; ‡Unite´ d’Oncologie Virale, Institut Pasteur, 75724, Paris Cedex 15, France; and
§Transgene SA, rue de Molsheim, 67000 Strasbourg, France
Received April 2, 1999; returned to author for revision May 17, 1999; accepted September 1, 1999
We have analyzed the nef gene sequences amplified from 12 macaques presenting various patterns of infection with
SIVmacBK28-41, a clone derived from attenuated SIVmacBK28. We have observed seven mutation hot spots at positions 56,
75, 432, 588, 680, 699, and 779. The major alteration was a thymidine insertion at position 699, leading to a frameshift in the
SIVmacBK28-41 nef gene and changing the last 15 amino acids of Nef into a 31-amino-acid-long C-terminal domain nearly
identical to that encoded by pathogenic SIVmac239 and SIVmac251. The insertion was found at early time points in proviruses
obtained from rapid progressor macaques, after 2 years postinfection in progressors, and rarely or only after 4 years
postinfection in nonprogressors. Fixation of the other mutations occurred only after insertion of thymidine 699. Phylogenetic
analysis demonstrated that the nef genes isolated from progressors evolved from the allele present in SIVmacBK28-41 to
alleles present in SIVmac239 or SIVmac251, whereas nef sequences from nonprogressors stayed clustered with that of the
inoculated molecular clone. These data stress the importance of the C-terminal extremity of the Nef protein of SIVmac239
or SIVmac251 in viral pathogenesis. © 2000 Academic PressINTRODUCTION
Monkeys infected with the simian immunodeficiency
virus (SIV) provide one of the best system for modeling in
vivo human immunodeficiency virus (HIV) infection and
studying the functions of the viral proteins and their
interactions with the host during the development of the
disease. Pathogenic SIV strains, such as SIVmac251,
induce an illness in macaques which closely resembles
that of HIV-infected patients, characterized by a primary
infection with a high viral load followed by an asymptom-
atic phase leading progressively to the development of
an AIDS-like disease (Daniel et al., 1987; Kestler et al.,
1988), whereas a more rapid disease can be observed
with variants like SIVsmmPBj14 (Fultz et al., 1989). Sev-
eral infectious molecular clones have been obtained,
some of them pathogenic, like the SIVmac239, but also
many of them displaying an attenuated phenotype
(Chakrabarti et al., 1987; Dewhurst et al., 1990; Franchini
t al., 1987; Hirsch et al., 1987; Kestler et al., 1988, 1990;
ornfeld et al., 1987; Luciw et al., 1992; Naidu et al., 1988).
For example, the SIVmacBK28 molecular clone, derived
from the pathogenic SIVmac251 isolate after several pas-
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28sages on a human T-cell line, can easily infect macaques
but the asymptomatic phase is far longer than that with
a pathogenic virus (Edmonson et al., 1998). One major
difference between attenuated SIVmacBK28 and patho-
genic SIVmac239 resides in the nef gene.
The Nef protein is now recognized as a key element of
viral pathogenesis not only in the simian model but also
during human infection (Harris, 1996; Kestler et al., 1990;
Spina et al., 1994). The nef gene, unique to lentiviruses of
primates, is localized in the 39 part of the viral genome,
overlapping the polypurine tract and a part of the U3
region in the LTR. This gene is massively transcribed
early in the viral cycle and produces a 25- to 35-kDa
protein which is subsequently myristylated and phos-
phorylated (Guy et al., 1987). Nef protein is involved in
downregulation of CD4 and MHC-I molecule surface
expression (Aiken et al., 1994; Garcia and Miller, 1991;
Guy et al., 1987; Hua and Cullen, 1997; Schwartz et al.,
1996), preventing superinfection of already infected cells
(Benson et al., 1993) and allowing them to resist killing by
cytotoxic T lymphocytes (CTL) (Collins et al., 1998). In
addition, Nef increases the viral particles’ infectivity as
well as the efficiency of reverse transcription (Aiken and
Trono, 1995; Luo et al., 1997, 1998; Miller et al., 1995;
Schwartz et al., 1995).
The in vivo importance of Nef was first observed dur-
ing the infection of rhesus macaques inoculated with
simian immunodeficiency virus (SIVmac) variants de-
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287C-TERMINAL DOMAIN OF SIVmac Nef AND PATHOGENICITYleted in the nef gene (Kestler et al., 1991). Contrary to
pathogenic SIVmac239 nef open, SIVmac239Dnef dem-
onstrated an attenuated phenotype in infected animals,
characterized by a viral load 100 times lower during the
primary infection, no plasmatic antigenemia, no CD41 T
lymphocyte depletion, and no clinical symptoms. A sim-
ilar discrepancy was also observed between macaques
infected with either C8 attenuated or J5 pathogenic vari-
ants of SIVmac32H, two molecular clones differing only
by point mutations and one in-frame deletion in the nef
gene (Rud et al., 1994). Likewise, nef genes obtained
from some HIV-1-infected nonprogressor humans are
altered by point mutations, small deletions, or the pres-
ence of a premature stop codon (Mariani et al., 1996).
Moreover, major alterations in the nef gene have been
observed in some human long-term nonprogressors
(LTNP) (Deacon et al., 1995; Kirchhoff et al., 1995; Salvi et
al., 1998). For example, eight individuals from the Sydney
Blood Bank cohort, infected by blood transfusions from a
single donor, presented a nonprogressive HIV infection
for almost 10 years (Deacon et al., 1995). The nef genes
of viruses amplified from these patients and from the
donor were shown to be partially deleted. By serological
analysis with Nef peptides, Greenway et al. (1998) dem-
onstrated that the single initial nef deletion present in the
virus from the donor had evolved in the recipients with a
loss of up to 80% of the nef sequence. It was proposed
that the lack of a functional nef gene was responsible for
the viral attenuation and the absence of, or slow, clinical
evolution observed in these patients. Nevertheless, after
a longer period of observation declining CD4 T-cell
counts were reported for patients with detectable
plasma viral load (Learmont et al., 1999).
In this study, we describe the in vivo evolution of the
nef gene amplified from rhesus macaques presenting
different patterns of clinical evolution after infection with
attenuated SIVmacBK28-41. The precise insertion of a
single nucleotide into the SIVmacBK28-41 nef sequence
allowed the expression of a different carboxyl terminal
extremity. This alteration, followed by specific point mu-
tations, is associated with an increase in cellular viremia
and viral pathogenicity in macaques, demonstrating the
importance of the C terminal extremity of SIVmac Nef
protein in viral virulence.
RESULTS
Infection of rhesus macaques with attenuated
SIVmacBK28-41
Eight rhesus macaques of a vaccination trial were
inoculated intravenously with 10 MID50 of molecular
clone SIVmacBK28-41 grown on macaque PBMC. This
attenuated SIV is derived from molecular clone SIV-
macBK28, in which the premature stop codon present in
the env gene was mutated in order to restore the com-
lete ORF. The animals were monitored for cell-associ-ted viral load and for CD41 and CD81 T lymphocyte
ounts, and all eight were found to be infected. During
rimary infection they had a detectable viral load ranging
rom 10 to 31,250 infected cells per million PBMC (Table
). No reduction in the initial viral load was observed for
he immunized animals compared to the control mon-
eys. Moreover, during follow up, some monkeys suf-
ered from a progressive immunodeficiency and three of
hem died from infection. Independently of the scheme of
mmunization, the rhesus macaques could be separated
nto three groups according to their clinical evolution and
requency of virus isolation (Table 1).
The first group comprises macaques who died within
.5 years postinfection and for which virus isolation was
lways positive. In group II, animals survived for more
han 3 years and had a frequently positive virus isolation
nd a reduced CD4/CD8 lymphocyte ratio, whereas virus
as not recovered for years, and no significant lympho-
yte depletion or symptoms were observed in group III.
Macaque PH440 was classified in group I. Its cell-
ssociated viral load varied between 10 and 250 infected
ells per million PBMC. The animal suffered a progres-
ive CD41 T lymphocyte depletion (from 1156 to 130
cells/ml, CD4/CD8 ratio from 1.07 to 0.03) and a severe
oss of weight (more than 50%) and ultimately died at 100
eeks postinfection with a characterized immunodefi-
iency.
Group II was composed of macaques 33593, 35830,
9114, and P2. The virus was isolated from these animals
uring the primary infection and was punctually recov-
red over the following 2 years. The cell-associated viral
oad increased thereafter. Macaques 33593 and 49114
ied with a partial depletion in CD41 T lymphocytes (273
nd 566 CD41 cells/ml, respectively) and a drop in the
D4/CD8 ratio to 0.4 and 0.8, respectively. Another mon-
ey was sacrificed because of TB positivity (35830). The
ast macaque (P2) was still alive 281 weeks postinfection
n spite of an immunosuppression (from 1010 to 160
D41 T lymphocytes/ml) and a CD4/CD8 ratio of 0.15.
Group III contained one macaque from each immuni-
zation regimen (33598, 49113, P6). During the primary
infection, the cell-associated viral load was similar to
that observed for the other macaques (10–6250 infected
cells per million PBMC). However, it decreased thereaf-
ter and the virus could never, or only on rare occasions
at very late time, be isolated by coculture over the fol-
lowing 4 years. These animals had no significant
changes in the CD41 T lymphocyte population and had
no clinical symptoms.
We have also included in this study four naive ma-
caques inoculated with SIVmacBK28-41 to establish
whether a similar difference of evolution could be ob-
served in the absence of previous immunization. The
follow up was less frequent during the asymptomatic
phase but on the basis of their immunological and viro-
logical parameters, one of these macaques (51190), who
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288 LAFONT ET AL.died 110 weeks postinfection, was included in group I.
Three others (51181, 51184, 51192), showing a reduced
CD4/CD8 ratio (0.7, 0.1, 0.9, respectively, at 3 years
postinfection), were included in group II.
nef gene sequence
As SIVmacBK28 was reported to be an attenuated
irus, we wanted to determine the reasons for the differ-
nces in the evolution of the infection in individual ani-
als and, particularly, the bases for the reversion to
athogenicity. We focused our analysis on the nef gene.
DNA was purified from PBMC or lymphoid organ cells
T
PBMC-Associated Viral Load in M
(A) Vaccin
Macaques:
Time pi
Group I Grou
PH440 33593 35830
1.5 50 10 10
4 250 10 10
9 50 1 1
13 250 1 —
21 10 10 —
44.5 50 — 2
72 10 50 10
100 ND 10 2
150 — —
195
216
231
Clinical status: Death Death Sacrifice
Time: W100 W152 W173
(B) Nai
Group I
Macaques: 51190
Time p.i.
2 400
4 4000
8 400
18 2
83 250
97 ND
Clinical status: Death
Time: W110
Note. The animals were classified according to their cell-associated
is expressed as the number of infected cells per million. Samples for w
dash. Times postinfection are expressed in weeks. Tissue samples wer
for nef gene sequencing without concomitant determination of the cell-
time point for the surviving macaques. ND, not determined.from the infected monkeys and was submitted to PCR
amplification with SIV nef-specific primers. Sequencing
s
Geactions were performed on PCR products and provide
ata on the predominant strain, although variant strains
resent in the sample in sufficient amount could also be
etected (Lang et al., 1997; Larder et al., 1993). The PCR
mplification and nef sequencing were performed on
amples obtained at 4, 100, 195, 216, and 231 weeks
ostinfection.
In the 42 samples analyzed, corresponding to 33,243
equenced nucleotides, we found 241 mutations in the
ef gene (792 bp from the start codon), among which 21
ere an insertion at a unique position (Table 2). Among
he other 220 mutations, we observed a majority of tran-
s Inoculated with SIVmacBK28-41
acaques
Group III
9114 P2 33598 49113 P6
250 31250 10 250 6250
10 1250 50 2 10
1 2 1 — —
— — 2 1 —
— 1 — — —
— — — — —
50 1 — — —
50 2 — — —
10 50 — — —
1 — — —
50 1 — —
50 — — 0.25
eath Alive Alive Alive Alive
179 W281 W281 W281 W28
aques
Group II
181 51184 51192
— 40 4000
0 40 40
00 4 4
0.4 —
— ND ND
ND 10 10
live Alive Alive
141 W155 W155
d and clinical evolution in three groups. The cell-associated viral load
he virus could not be isolated from 4 million PBMC are indicated by a
ted at necropsy on macaques PH440 (week 100) and 49114 (week 179)
ated viral load. Clinical status was given at time of death or at the lastABLE 1
acaque
ated m
p II
4
D
W
ve mac
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viral loa
hich t
e collecitions (transition/transversion ratio of 2.85), with the A to
and G to A transitions being the most represented. No
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289C-TERMINAL DOMAIN OF SIVmac Nef AND PATHOGENICITYmutation created a premature stop codon and they were
unequally distributed on the nef gene (Fig. 1). Some
regions were preserved, such as the 59 extremity, the
polypurine track, or the sequences corresponding to
putative structural domains (Lee et al., 1996). In contrast,
other areas concentrated a lot of mutations, such as the
regions between nucleotides 103–159, 301–357, and
T
Distribution of the Mutations between the Gr
Number of
Macaques Sequences Nucleotides
Group I 2 5 3959
roup II 7 20 15,833
roup III 3 17 13,833
ith insertion NA 21 16,632
ithout insertion NA 21 16,611
P value for
Group I versus group II 0
Group I versus group III P ,
Group II versus group III P ,
Note. The proviral sequence was determined on a tissue sample (PB
mixed population was observed at a precise location, like the inser
xcluded, as we did not evaluate the proportion precisely. NA, not app
a The insertion in position 699 of the nef gene was considered as o
b The variability (%) was calculated on the nucleotide sequence taki
c Insertion: number of sequences having the insertion of one thymidi
ef length. Insertion frequency was calculated with the sequences coll
for independence using StatXact-3 software.
FIG. 1. Distribution of the mutations on the SIVmacBK28-41 nef gene.
rom the nef start codon. Gray bars represent localization of the mut
equence differences between SIVmacBK28-41 and SIVmac239 nef o
eading frame. Sequences encoding the structural domains described by Lee e
lack and one gray horizontal bars (Lee et al., 1996).562–636, representing ;42% of the mutations. Moreover,
7 mutation hot spots were found in positions 56, 75, 432,
588, 680, 699, and 779, representing nearly 40% of all
mutations. The mutation in position 75 was silent,
whereas mutations in positions 56, 432, 588, 680, and
779 were nonsynonymous. The mutation in position 699
was an insertion of one thymidine leading to a frameshift
r in Function of the Insertion in Position 699
Sequence
variability (%)b
Insertion in
position 699c
Insertion
frequency (%)utationsa
48 1.21 4/5 80
169 1.07 13/20 65
24 0.18 4/17 23
239 1.44 21/21 100
2 0.01 0/21 0
on only P value for seven hot spots
0.25
P , 0.005
P , 0.001
ph node, or spleen cell) taken at a time point from one animal. When
699, only the majority was considered and the subpopulations were
.
ation event.
account the number of insertions.
osition 699 of the nef gene, restoring the nef ORF to a SIVmac239-like
t all time points. Probabilities were determined with Pearson’s x2 test
tations are distributed on a 792-bp SIVmacBK28-41 sequence starting
found in the nef gene of the infected macaques. Black bars localize
e star marks the position of the insertion in 699 changing the openABLE 2
oups o
M
inserti
.47
0.05
0.05
MC, lym
tion in
licable
ne mut
ng into
ne in pThe mu
ations
pen. Tht al. and the polypurine track (PPT) are depicted, respectively, by eight
i
the num
290 LAFONT ET AL.in the nef ORF and changing the last 15 amino acids of
SIVmacBK28-41 Nef protein into a 31-amino-acid-long
C-terminal extremity nearly identical to that encoded by
SIVmac239 (Fig. 2). Interestingly, the majority of muta-
tions was found in provirus sequences already harboring
the insertion in position 699 (Table 2).
We thereafter sequenced the nef gene of SIVmac251
virions produced on macaque PBMC. We observed 23
mutations compared with the sequence of SIVmacBK28,
16 being identical to mutations found in the SIVmac239
nef gene. The insertion in position 699 was present, as
well as 5 of the 6 other hot spots (the nucleotide in
FIG. 2. Alignment of the predicted Nef protein sequences obtained fro
chronologically per animal. Each sequence denomination is compos
peripheral blood mononuclear cell; LN, lymph node; or SP, spleen cells
identified the nef sequence obtained from macaque PH440 with PBM
insertion in 699, a mixed population was observed, only the majority w
not evaluated precisely. We used the sequence of SIVmacBK28-41 for re
mutations and in bold lowercase letters for the synonymous mutations.
stop codon, respectively. localizes the seven mutation hot spots. Fo
nsertion is written in normal capitals, with the mutation written in bold
to those described by Lee et al. for HIV-1 Nef protein, are localized over
protein kinases.position 432 was the same as that in SIVmacBK28).
Moreover, we carried out nef sequencing on RT–PCRfragments obtained from virus isolated from macaques
PH440 (week 97 postinfection), 49114 (week 100), 35830
(week 100), and P2 (week 231). In all cases, the se-
quences were similar to that of the provirus analyzed at
the same time, which demonstrates that our proviral nef
data reflected the sequences of infectious viruses.
Impact of thymidine insertion in position 699 on
clinical evolution
We then studied whether the distribution of the thymi-
dine insertion was similar in the three groups. Four
macaques infected with SIVmacBK28-41. The sequences are classified
e three last digits of the animal’s tattoo, the tissue sample (PBMC,
e time postinfection expressed in weeks. For example, 440-PBMC-W4
n at 4 weeks postinfection. When on a precise location, such as the
sidered, and the subpopulations were excluded as the proportion was
e. The mutations are indicated in bold capitals for the nonsynonymous
ts and stars indicate amino acids identical to SIVmacBK28-41 and the
equences having the insertion in 699, the protein sequence after the
ters. The structural domains, four a helix and four beta sheets, similar
eration. PPII indicates the PXXP motif which interacts with the cellularm the
ed of th
) and th
C take
as con
ferenc
The do
r the s
characweeks postinfection, the proviruses bore a nef gene
identical to the SIVmacBK28 gene for all animals with
T
r
s
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291C-TERMINAL DOMAIN OF SIVmac Nef AND PATHOGENICITYtwo exceptions (Table 1, Fig. 2). One monkey of group II
(P2) had a mixed population of nef genes, the major
population being identical to that of the nef gene of the
other animals, whereas the minor population already had
the insertion of one thymidine in position 699 which
restored the ORF to a length similar to that of SIVmac239
nef open. The nef genes obtained from macaque PH440
(group I) were also a mixed population, with the majority
carrying the thymidine insertion. Sequences obtained
from spleen and lymph node samples collected at nec-
ropsy on this macaque (100 weeks postinfection)
showed that only the provirus with the T insertion could
be recovered from these two organs. At the same time,
the nef sequences obtained from macaque PBMC of
group II had reverted, whereas no change was found on
the nef gene in group III. Later during infection two
animals from group II died and the evolution of nef
sequences obtained from lymph node and spleen cells
of macaque 49114 was similar to that of macaque PH440.
he original nef allele was undetectable and only provi-
FIG. 2us harboring the T insertion was found. In addition,
ome nonconservative mutations accumulated. Similarobservations were made with the nef sequences of P2,
with a more pronounced effect of mutation fixation (Fig.
2). The situation is more complex in group III. In one
macaque (P6), where the viral load remained below the
threshold of quantitation after 4 weeks postinfection,
except on one occasion, the nef gene conserved a SIV-
macBK28-type sequence in the PBMC as well as in the
lymph nodes. In a second animal (49113), the insertion
was found first in the lymph node at week 216 (the nef
sequence could not be obtained at that time from the
PBMC, presumably because of very low viral load) and
15 weeks later in PBMC and lymph nodes. In macaque
33598, the virus was detected at two time points. The nef
sequences were of the SIVmacBK28 type in PBMCs and
of the SIVmac239 type in a lymph node at week 216,
whereas at week 231 the nef population was mixed in
PBMCs and without T699 insertion in another lymph
node. It is possible that, as viral replication resumed after
4 years, the distribution of virus carrying the SIVmac239
type nef gene was heterogeneous in the animal’s body.
inuedThe sequence data showed that the insertion occurred
early in group I, later in group II, with the exception of P2
—Cont
292 LAFONT ET AL.(4 weeks), and more than 4 years postinfection or it has
not occurred after this time in group III. Moreover, the
overall nef sequence variability decreased from 1.21% in
group I to 0.18% in group III (Table 2).
A phylogenetic analysis was performed with the 46 nef
sequences using SIVmacBK28 and SIVmac239 nef se-
quences as references (Fig. 3). The sequences obtained
at an early stage clustered around SIVmacBK28, reflect-
ing the homogeneity of the molecular clone inoculated.
Later sequences of group III were also found in the same
cluster, whereas sequences of group I (PH440, 51190)
and group II (33598, 49114, 35830, P2, 51184, 51181,
51192) tended to evolve toward the SIVmac239 nef se-
quence. A progressive evolution could be observed for
macaques 49114, PH440, and P2. The analysis of the
protein sequences encoded by the nef gene demon-
strated that the fixation of mutations occurred with a
fixed order (Table 3). The first event was the insertion in
699 of a thymidine leading to a frameshift and expression
FIG. 2of a SIVmac239-type Nef C-terminal domain. The second
mutation was a C to T transition at position 680, convert-ing the Ala 227 into Val. The third event was an A to G
transition at position 779, changing the Arg 260 into Lys.
All these mutations were found in the macaques of
groups I and II. In group III the thymidine insertion was
found on rare occasions and at most one of the two other
mutations (680, 779) was observed on the nef se-
quences.
DISCUSSION
In this study, we have demonstrated the importance of
the C-terminal domain of the SIVmac Nef protein by
analyzing the in vivo evolution of the nef gene. We have
shown that recovery of virulence in the macaque is
associated with the insertion of one nucleotide convert-
ing the C-terminal extremity of the SIVmacBK28-41 Nef
protein into the domain of pathogenic SIVmac239.
Indeed, we have monitored two independent groups of
rhesus macaques infected by the SIVmacBK28-41 mo-
inuedlecular clone, derived from the attenuated molecular
clone SIVmacBK28 by restoration of a full-length gp41.
Denom
lack. Se
293C-TERMINAL DOMAIN OF SIVmac Nef AND PATHOGENICITYThis modification has been shown to increase slightly
the pathogenicity of the virus by shortening the median
survival time from 7 years to less than 3 years (2/3
FIG. 3. Phylogenetic analysis of the nef sequences. The phylogeneti
for sequences without the insertion in position 699) starting at the Ne
Megalign program (Lasergene package, DNASTAR Inc., Wisconsin).
sequences of SIVmac239 and of the inoculated SIVmacBK28-41 are in banimals) (Edmonson et al., 1998).
The clinical, hematological, and virological data allowedus to classify the infected monkeys into three separate
groups. The first group was composed of macaques devel-
oping an AIDS-like disease in less than 2 years (rapid
sis was performed on the 792-bp sequences of the nef genes (791 bp
odon. The sequences were aligned with the Clustal method from the
ination of the sequences was identical to that of Fig. 2. Reference
quences of groups I, II, and III are, respectively, in red, blue, and green.c analy
f start cprogressors). The outcome of the illness was delayed for
the second group (progressors), whereas no clinical evo-
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294 LAFONT ET AL.lution was observed in the third group (nonprogressors), at
least up to 281 weeks postinfection.
Three reasons prompted us to examine the nef gene
rom the provirus carried by these animals. First, a com-
lete Nef protein is an important factor for the mainte-
ance of a high viral load (Kestler et al., 1991), a now
well-recognized prognostic criterion indicative of a rapid
development of AIDS and death (Ho, 1996; Mellors et al.,
1996; Ten Haaft et al., 1998). Second, the follow up of
some LTNP has indicated that HIV-1 with nef alteration
could be responsible for the clinical nonprogression of
certain infected individuals. Third, the nef sequence of
attenuated SIVmacBK28-41 differs from the sequence of
the pathogenic SIVmac239 nef open molecular clone by
23 point mutations and the deletion of one nucleotide
generating a Nef protein with all structural domains in-
tact but carrying a different C-terminal extremity. As the
crystal and solution structures of HIV-1 Nef protein have
been determined recently (Grzesiek et al., 1996; Lee et
al., 1996), it is possible to identify the putative structural
domains in the SIV Nef protein on the basis of the
conserved amino acids. The majority of the mutations
described in our study cluster in two unstructured do-
mains localized in the N-terminal domain and between
the C and D beta sheets (see Figs. 1 and 2). This is not
surprising since similar data were obtained for the HIV-1
nef gene in humans and for the SIVmac239 nef gene in
macaques (Shugars et al., 1993; Zhu et al., 1996). No
T
Order of Mutation Fixatio
Macaque Time p.ia 680
SIVmacBK28 GCT Al
PH440 4 GCT Al
100 GTT Va
P2 4 GCT Al
100 GTT.GCT V
195 GTT Va
216 GTT Va
231 GTT Va
49114 4 GCT Al
100 GCT Al
179 LN GTT Va
179 SP GTT Va
SIVmac239 GTT Va
SIVmac251 GTT Va
Note. Examples of three hot spots (680, 699, and 779) are given for t
the letters LN (lymph node) and SP (spleen) specify the tissue from wh
TTG codon into TTT G, changing the open reading frame. When a mixed
by the . sign.
a The time postinfection of the sequences is given in weeks.
b This codon encoding an arginine is located outside the Nef ORF imutation altered the domains indispensable for viral rep-
lication, such as the polypurine track, or regions involved
n
ain protein maturation, such as the myristylation site, the
phosphorylation sites, or the PXXP kinase-binding do-
main. Nevertheless, the sequence adjacent to the PXXP
domain was found to be mutated in one macaque (51184
at 97 weeks postinfection), creating a (PXXP)2 domain
similar to the kinase interaction site of HIV-1 Nef. The
mutation converting Ala 136 into Glu may be due to the
selection of a CTL escape mutant in the infected ma-
caque, as it altered a CTL epitope describe in SIVmac251
Nef protein (Mortara et al., 1998). Interestingly, Mortara et
al. suggested that the CTL response in Nef-immunized
macaques challenged with SIVmac251 is responsible for
the selection of a minor population with Ala 136 changed
into Thr. Furthermore, seven hot spots of mutation were
identified, two of them are located in sequences encod-
ing the unstructured N-terminal extremity, two in the B
and D a helix, one in the unstructured loop between the
C and D beta sheets, and one in the C-terminal domain.
All these mutations can also be found in the sequence of
the SIVmac239 nef gene. In their study on the evolution
f SIVmacBK28 pathogenicity, Edmonson et al. (1998)
ave observed, in a variant having acquired an in-
reased virulence, mutations residing in six of the seven
ot spots of mutation described here.
The major alteration in the nef sequences analyzed
as the insertion of one thymidine in position 699, cre-
ting a frameshift and allowing synthesis of a Nef protein
ith a SIVmac239 type C-terminal extremity. This phe-
e SIVmacBK28 nef Gene
Mutation position and amino acid change
699 779
TTG Leu AGG Argb
TTT.TTG Phe.Leu AGG Arg
TTT Phe AAG Lys
TTG.TTT Leu.Phe AGG Arg
a TTT Phe AGG Arg
TTT Phe AGG Arg
TTT Phe AAG Lys
TTT Phe AAG Lys
TTG Leu AGG Argb
TTT Phe AGG Arg
TTT Phe AAG Lys
TTT Phe TGG Trp
TTT Phe AAG Lys
TTT Phe AAG Lys
acaques (PH440, group I; P2 and 49114, group II). For macaque 49114,
sequences were obtained. The insertion in position 699 converts the
ation was observed, the major and the minor populations are specified
acBK28-type sequences.ABLE 3
n in th
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ich the
populomenon was observed for all animals in groups I and II
nd for some of the animals in group III at a very late time
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295C-TERMINAL DOMAIN OF SIVmac Nef AND PATHOGENICITYafter infection. Following this, a series of mutations oc-
curred in the D a helix and in the C-terminal extremity.
he frequencies of insertion and nef variability were
igher in macaques from group I and decreased from
roup II to group III. As lentiviral variability is related to
iral replication, the presence of the insertion in 699 and
he expression of the C-terminal domain may be associ-
ted with an increase in viral replication followed by an
cceleration in viral pathogenesis.
In vivo restoration of Nef protein is not an uncommon
henomenon. The initial SIVmac239 molecular clone
ossesses a premature stop codon at position 93 (Regier
nd Desrosiers, 1990), but in vivo the TAA mutates into
AA (Glu), restoring the nef ORF and the viral capacity to
nduce an AIDS-like disease in macaques (Kestler et al.,
991; Zhu et al., 1996). Two molecular clones, the J5
athogenic and the C8-attenuated viruses, were ob-
ained from the SIVmac32H isolate. They differ only by a
2-bp-long in-frame deletion in the sequence encoding
he B a helix of C8 Nef protein. However, after a certain
ime of infection, some animals inoculated with the at-
enuated C8 virus evolve clinically to AIDS, the restora-
ion of viral pathogenesis being linked to the restoration
f the 12 bp by a sequence duplication process (What-
ore et al., 1995). In contrast to these two examples,
here structural domains were completely (SIVmac239
ef stop) or partially (C8 virus) lost, SIVmacBK28-41 had
ll the structural elements, and after evolution the last 15
mino acids were replaced by 31 amino acids, due to the
rameshift. Despite being alterated and encoding a
horter protein, no deletion was detected in the nef gene
f SIVmacBK28-41. This suggests that the Nef protein of
his virus is at least partially functional. Indeed, progres-
ive extension of nef deletion was observed for viruses
ith nonfunctional nef genes (Deacon et al., 1995; Kirch-
off et al., 1994). The mechanism involved in the resto-
ation of the nef gene in SIVmacBK28-41 is probably the
tuttering of the reverse transcriptase allowing the inser-
ion, next to two thymidines, of a third one in position 699.
The unique site of insertion stressed the functional
ifference between SIVmacBK28 and the SIVmac239-
ype Nef C-terminal extremity. Moreover, the order of
utation fixation suggests that expression of the C-ter-
inal domain requires some structural adjustments,
eading to selection of the nef gene with the other mu-
ations identified. The synthesis of a Nef protein with a
IVmac239-type C-terminal extremity confers a structural
nd/or functional advantage to the virus. It has been
hown previously that replacing the last 38 amino acids
f SIVmac239 Nef with the last 11 residues of HIV-1 SF2
ef dramatically decreases the stability of the transiently
xpressed protein (Garcia and Foster, 1995).
Stabilisation of the Nef protein in infected cells could
hus increase its in vivo activity and, consequently, viral
athogenicity. However, we cannot exclude the fact that
ther variations in the lentiviral genome, in particular the
F
Fnv gene, contribute to increased virulence. Neverthe-
ess, we can rule out the involvement of a fourth SP1
inding site in the LTR of the SIVmac251 isolate and
IVmac239, as it was never observed in our sequence
nalysis of SIVmacBK28-41 variants.
MATERIAL AND METHODS
irus
The molecular clone SIVmacBK28-41 is derived from
IVmacBK28 (kindly provided by Dr. J. Mullins), in which
he premature stop codon present in the env gene was
utated in order to restore a complete env ORF (Dunn et
l., 1997). This premature stop codon, probably due to
irus cultivation in human cells, was shown to revert
pontaneously in vitro in simian cells and in vivo in
nfected macaques (Hirsch et al., 1989; Kodama et al.,
989). This restoration, however, only marginally in-
reases the virulence of SIVmacBK28 (Edmonson et al.,
998). The virus stock was produced on macaque PBMC
nd titrated in rhesus macaques (Dunn et al., 1997).
The SIVmac251 isolate, kindly provided by Dr. R. Des-
osiers, was propagated on macaque PBMC.
nimals
Rhesus macaques were maintained according to the
onditions stipulated in the European guidelines. All the
nimals were handled only after sedation with ketamine
Cl (10 mg/kg; Imalgene, Me´rieux). The animals were
noculated with cell-free virus stock in the saphenous
ein. Blood samples were collected by femoral venipunc-
ure.
A total of 12 rhesus macaques, forming two indepen-
ent groups, were studied: 8 were included in a vacci-
ation protocol and 4 were used for in vivo titration of the
IVmacBK28-41 stock. For the vaccination trial, 6 ma-
aques were immunized with recombinant vaccinia vi-
uses expressing either gag (vvTG4137—macaques
H440, 33598, 35830, P2) or gag-pol-env of SIVmac251
vvTG6131—macaques 49113, 49114). Two control mon-
eys were immunized with wild-type vaccinia virus (ma-
aques P6, 33593) and all the animals were challenged
ntravenously with 10 MID50 of SIVmacBK28-41 grown on
acaque PBMC. The second monkey group, used for
itration of the SIV stock, was formed by macaques
1192, 51184, 51190, and 51181. They were inoculated,
espectively, with 32, 3.2, 1.6, and 0.8 MID50 of SIV-
acBK28-41 (Dunn et al., 1997).
mmunophenotyping
A standard whole blood staining method was used.
riefly, whole blood samples were incubated with anti-
D4-PE (OKT4-PE, Ortho, Roissy, France) and anti-CD8-
ITC (Leu2a-FITC, Becton–Dickinson, Le Pont de Claix,
rance). Red blood cells were lysed with the “lyse and fix
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(Immunotech, Luminy, France). Cell suspensions were
washed, centrifuged, and then analyzed on a FACScan
flow cytometer (Becton–Dickinson) in a lymphocyte gate
defined by the FSC–SSC parameters, containing at least
5000 events.
Cell-associated viral load determination
Macaque PBMC were purified from heparinized blood
by density gradient centrifugation on a Ficoll–Hypaque
cushion (Eurobio, France). The quantitative determina-
tion of the cell-associated viral load was performed by
cocultivating 2.5 3 106, 106, 5 3 105, and fivefold serial
dilutions of the primary cells with 1.5 3 105 CEMx174
cells in 24-well plates. The cocultures were maintained
for 4 weeks and treated twice weekly, once to change the
culture medium (RPMI 1640 1 10% fetal calf serum
heated at 56°C for 30 min 1 2 mM Glutamax 1 100
mg/ml streptomycin 1 100 IU/ml penicillin) and once to
divide the cells. The reverse transcriptase (RT) activity
was determined at each time (Moog et al., 1994) and its
increase was taken as evidence of viral replication. The
cell-associated viral load was expressed as the number
of infected cells per 106 cells.
Lymph nodes were dilacerated with scissors and cells
were dissociated by vigorous pipetting and then filtrated
through a 70-mm gauze to obtain a single-cell suspen-
sion. The cells were pelleted and washed twice in PBS
before being counted and cocultured as described
above for the PBMC.
nef amplification and sequencing
DNA of PBMC, spleen, or lymph node cells was ex-
tracted by a phenol–trichloroethane technique following
proteinase K digestion. Briefly, pellets of 106 cells were
resuspended in 1 ml of lysis buffer (50 mM Tris–HCl, pH
7.4, 5 mM EDTA, 0.25% SDS, 150 mM NaCl, and 200
mg/ml Proteinase K) and incubated for 2 h at 56°C. The
DNA was then extracted with phenol/trichloroethane and
was ethanol-precipitated. After centrifugation, the DNA
pellet was washed once with ethanol 70%, dried, and
solubilized in 100 ml water.
DNA was submitted to PCR amplification with SIVmac
nef-specific primers. A first PCR reaction was performed
with NEF1 sense and NEF2 reverse primers. When a
signal could not be detected, two heminested PCR reac-
tions were performed in order to increase the amplifica-
tion. NEF1 was used with reverse primer BO7096,
whereas sense primer BO7095 was used with NEF2.
This procedure was applied instead of a nested PCR
reaction in order to avoid the loss of sequence data due
to internal localization of the nested primers in the nef
gene sequence. The PCR amplifications were carried out
in a DNA thermal cycler (Perkin–Elmer) in a 100-ml reac-
ion volume consisting of 75 mM Tris–HCl, pH 9.0, 20 mMNH4)2SO4, 0.01% (w/v) Tween 20, 2.5 mM MgCl2, 200 mM
NTP, 35 pmol each sense and reverse primer, and 1.5 U
f Gold Star DNA polymerase (Eurogentec, Serain, Bel-
ium). The amplification program with NEF1 and NEF2
rimers was as follows: 5 min denaturation at 95°C, 40
ycles of 1 min at 95°C, 1 min at 66°C, and 1 min at
2°C, and finally 10 min at 72°C. The heminested reac-
ions were performed similarly: 25 cycles were used for
hese PCR amplifications and the hybridization temper-
tures were 66°C for NEF1/BO7096 and 64°C for the
EF2/BO7095. The primer sequences were the follow-
ng: NEF1, 59-AGGCTCTCTGCGACCCTACGA-39, nucleo-
ide positions 8995–9015 on SIVmacBK28 genome (Gen-
ank Accession No. M19499); NEF2, 59-AGAACCTC-
CAGGGCTCAATCT-39, positions 9994–9973; BO7095,
9-CCTACCTACAATATGGGTGGAGC-39, positions 9047–
069; and BO7096, 59-CCTCTGACAGGCCTGACTTGCT-
CC-39, positions 9781–9756. The PCR products were
eparated on a 2% agarose gel and purified with the
izard PCR preps DNA purification System (Promega
orp., Madison, WI) according to the manufacturer’s
pecifications. The sequencing reactions were per-
ormed directly on the PCR products by Genome Express
ompany (Grenoble, France) using the fluorescent
ideoxynucleotide terminator protocol and analyzed on
n automated 377 ABI Prism sequencer.
Determination of major and minor populations was
ased on the fluorescence intensity of each nucleotide
ignal. As demonstrated by sequencing PCR products of
ixtures of matrix with and without insertion in different
roportions, our PCR system allows the detection of a
inor population representing 25% of the mixture but not
f present at 10%.
ef RT–PCR amplification from viral suspension
Genomic RNA of SIVmac251 or viral isolates was
xtracted by mixing 250 ml viral suspension with 750
ml Tri Reagent (Molecular Research Center Inc., Cin-
inatti, OH). After 5 min, 200 ml of trichloroethane was
added and 5 min later the aqueous phase was recov-
ered after centrifugation. The viral RNA was isopropa-
nol-precipitated, pelleted by centrifugation, and
washed with 70% ethanol. The RNA pellet was solubi-
lized in 25 ml water.
Reverse transcription was carried out in 20 ml contain-
ng 35 pmol NEF2 reverse primer, 2 ml of 103 PCR Buffer
I (Perkin–Elmer Applied Biosystem Division, Foster City,
A), 5 mM MgCl2, 1 mM dNTP, 20 U RNAsin (Pharmacia
Biotech, Uppsala, Sweden), and 50 U MuLV reverse tran-
scriptase (Perkin–Elmer) and incubated for 30 min at
42°C. The nef sequence was amplified by PCR as de-
scribed above for genomic DNA except that the NEF2
reverse primer, already present in the sample, was not
added again in the PCR mix.
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297C-TERMINAL DOMAIN OF SIVmac Nef AND PATHOGENICITYSequence analysis
The nef sequences were reconstructed with the Edit-
seq and Seqman softwares of the Lasergene package
(Dnastar, Wisconsin). The nef sequences, covering 792
bp from the start codon (791 bp for SIVmacBK28), were
aligned and a phylogenetic analysis was obtained using
the Clustal method of the Megalign software. As refer-
ences for our analysis, we have used the sequences of
SIVmacBK28 and SIVmac239 (GenBank Accession No.
M33262). For SIVmac239, the nef open sequence was
chosen since the premature stop codon present at
codon 93 reverts spontaneously in infected macaques
(Kestler et al., 1991; Regier and Desrosiers, 1990; Zhu et
al., 1996).
Statistical method
Pearson’s x2 test for independence was used to com-
are the distribution of the 699 insertion using the StatX-
ct-3 software (Cytel Software Corp., Massachusetts).
or hot spot mutations the presence of zero to seven
utations was compared between the groups using
earson’s x2 test for independence with the Monte Carlo
estimation.
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